BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37742181)

  • 1. Optogenetic induction of alpha-synuclein aggregation in human dopaminergic neurons to model Parkinson's disease pathology.
    Ra EA; Kim MS; Lee G
    STAR Protoc; 2023 Dec; 4(4):102609. PubMed ID: 37742181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation.
    Kim MS; Ra EA; Kweon SH; Seo BA; Ko HS; Oh Y; Lee G
    Cell Stem Cell; 2023 Jul; 30(7):973-986.e11. PubMed ID: 37339636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optogenetic-mediated induction and monitoring of α-synuclein aggregation in cellular models of Parkinson's disease.
    Teixeira M; Sheta R; Idi W; Oueslati A
    STAR Protoc; 2023 Dec; 4(4):102738. PubMed ID: 37991922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.
    Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A calcineurin- and NFAT-dependent pathway is involved in α-synuclein-induced degeneration of midbrain dopaminergic neurons.
    Luo J; Sun L; Lin X; Liu G; Yu J; Parisiadou L; Xie C; Ding J; Cai H
    Hum Mol Genet; 2014 Dec; 23(24):6567-74. PubMed ID: 25051958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease.
    Brazdis RM; Alecu JE; Marsch D; Dahms A; Simmnacher K; Lörentz S; Brendler A; Schneider Y; Marxreiter F; Roybon L; Winner B; Xiang W; Prots I
    Hum Mol Genet; 2020 May; 29(7):1180-1191. PubMed ID: 32160287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.
    Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Toxicol Sci; 2015 Feb; 143(2):454-68. PubMed ID: 25416158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
    Sharma N; Rao SP; Kalivendi SV
    Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide.
    Zunke F; Moise AC; Belur NR; Gelyana E; Stojkovska I; Dzaferbegovic H; Toker NJ; Jeon S; Fredriksen K; Mazzulli JR
    Neuron; 2018 Jan; 97(1):92-107.e10. PubMed ID: 29290548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
    Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
    FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein pathology is associated with astrocyte senescence in a midbrain organoid model of familial Parkinson's disease.
    Muwanigwa MN; Modamio-Chamarro J; Antony PMA; Gomez-Giro G; Krüger R; Bolognin S; Schwamborn JC
    Mol Cell Neurosci; 2024 Mar; 128():103919. PubMed ID: 38307302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional expression of Parkinson's disease-related mutant α-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1.
    Lin X; Parisiadou L; Sgobio C; Liu G; Yu J; Sun L; Shim H; Gu XL; Luo J; Long CX; Ding J; Mateo Y; Sullivan PH; Wu LG; Goldstein DS; Lovinger D; Cai H
    J Neurosci; 2012 Jul; 32(27):9248-64. PubMed ID: 22764233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
    Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
    J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell transcriptomics identifies perturbed molecular pathways in midbrain organoids using α-synuclein triplication Parkinson's disease patient-derived iPSCs.
    Patikas N; Ansari R; Metzakopian E
    Neurosci Res; 2023 Oct; 195():13-28. PubMed ID: 37271312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease.
    Yang Y; Song JJ; Choi YR; Kim SH; Seok MJ; Wulansari N; Darsono WHW; Kwon OC; Chang MY; Park SM; Lee SH
    Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2110746119. PubMed ID: 35858361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
    Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
    J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Glial Activation and α-Synuclein Pathology in Parkinson's Disease.
    Wang R; Ren H; Kaznacheyeva E; Lu X; Wang G
    Neurosci Bull; 2023 Mar; 39(3):479-490. PubMed ID: 36229715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.